Monoamine-oxidase A and B inhibitors, irreversible(continued)
▶Monoamine-oxidase A and B inhibitors, irreversibleare
predicted to increase the risk of side-effects when given with
linezolid. Avoid and for 14 days after stopping the MAOI.
rTheoretical→Also seeTABLE 13p. 850
▶Monoamine-oxidase A and B inhibitors, irreversibleare
predicted to alter the antihypertensive effects ofmethyldopa.
Avoid.rTheoretical→Also seeTABLE 8p. 848
▶Methylphenidateis predicted to increase the risk of a
hypertensive crisis when given withmonoamine-oxidase A and
B inhibitors, irreversible. Avoid and for 14 days after stopping
the MAOI.rTheoretical
▶Mianserinis predicted to increase the risk of toxicity when
given withmonoamine-oxidase A and B inhibitors, irreversible.
Avoid and for 14 days after stopping the MAOI.r
Theoretical→Also seeTABLE 13p. 850
▶Monoamine-oxidase B inhibitors(rasagiline, selegiline)are
predicted to increase the risk of side-effects when given with
monoamine-oxidase A and B inhibitors, irreversible. Avoid and
for 14 days after stopping the MAOI.rTheoretical→Also
seeTABLE 8p. 848→Also seeTABLE 13p. 850
▶Monoamine-oxidase B inhibitors(safinamide)are predicted to
increase the risk of side-effects when given withmonoamine-
oxidase A and B inhibitors, irreversible. Avoid and for 1 week
after stoppingsafinamide.rTheoretical→Also seeTABLE 13
p. 850
▶Nefopamis predicted to increase the risk of serious elevations
in blood pressure when given withmonoamine-oxidase A and B
inhibitors, irreversible. Avoid.rTheoretical
▶Opicaponeis predicted to increase the risk of elevated blood
pressure when given withmonoamine-oxidase A and B
inhibitors, irreversible. Avoid.rTheoretical
▶Opioidsare predicted to increase the risk of CNS excitation or
depression when given withmonoamine-oxidase A and B
inhibitors, irreversible. Avoid.rStudy→Also seeTABLE 13
p. 850
▶Monoamine-oxidase A and B inhibitors, irreversibleare
predicted to increase the risk of neuroleptic malignant
syndrome when given withphenothiazines.rTheoretical→
Also seeTABLE 8p. 848
▶Pholcodineis predicted to increase the risk of CNS excitation
or depression when given withmonoamine-oxidase A and B
inhibitors, irreversible. Avoid and for 14 days after stopping
the MAOI.rTheoretical
▶Reboxetineis predicted to increase the risk of a hypertensive
crisis when given withmonoamine-oxidase A and B inhibitors,
irreversible. Avoid.rTheoretical
▶Monoamine-oxidase A and B inhibitors, irreversibleare
predicted to increase the exposure torizatriptan. Avoid and
for 14 days after stopping the MAOI.rTheoretical→Also
seeTABLE 13p. 850
▶Monoamine-oxidase A and B inhibitors, irreversibleare
predicted to increase the exposure tosumatriptan. Avoid and
for 14 days after stopping the MAOI.rTheoretical→Also
seeTABLE 13p. 850
▶Monoamine-oxidase A and B inhibitors, irreversibleare
predicted to increase the risk of a hypertensive crisis when
given withsympathomimetics, inotropic. Avoid and for 14 days
after stopping the MAOI.rTheoretical
▶Monoamine-oxidase A and B inhibitors, irreversibleare
predicted to increase the risk of a hypertensive crisis when
given withsympathomimetics, vasoconstrictor. Avoid and for
14 days after stopping the MAOI.rStudy
▶Tetrabenazineis predicted to increase the risk of CNS toxicity
when given withmonoamine-oxidase A and B inhibitors,
irreversible. Avoid and for 14 days after stopping the MAOI.
rTheoretical
▶Tolcaponeis predicted to increase the effects ofmonoamine-
oxidase A and B inhibitors, irreversible. Avoid.rTheoretical
▶Tricyclic antidepressantsare predicted to increase the risk of
severe toxic reaction when given withmonoamine-oxidase A
and B inhibitors, irreversible. Avoid and for 14 days after
stopping the MAOI.rTheoretical→Also seeTABLE 8
p. 848→Also seeTABLE 13p. 850▶Tryptophanincreases the risk of side-effects when given with
monoamine-oxidase A and B inhibitors, irreversible.r
Anecdotal→Also seeTABLE 13p. 850
▶Monoamine-oxidase A and B inhibitors, irreversibleare
predicted to increase the exposure tozolmitriptan.r
Theoretical→Also seeTABLE 13p. 850
Monoamine-oxidase B inhibitors→seeTABLE 6p. 848
(bradycardia),TABLE 8p. 848 (hypotension),TABLE 13p. 850 (serotonin
syndrome)
rasagiline.safinamide.selegiline..FOOD AND LIFESTYLEHypertension is predicted to occur when
high-doseselegilineis taken with tyramine-rich foods (such
as mature cheese, salami, pickled herring,Bovril®,Oxo®,
Marmite®or any similar meat or yeast extract or fermented
soya bean extract, and some beers, lagers or wines).
▶Monoamine-oxidase B inhibitors(rasagiline, selegiline)are
predicted to increase the risk of severe hypertension when
given withamfetamines. Avoid.rTheoretical→Also see
TABLE 13p. 850
▶Safinamideis predicted to increase the risk of severe
hypertension when given withamfetamines.r
Theoretical→Also seeTABLE 13p. 850
▶Monoamine-oxidase B inhibitors(rasagiline, selegiline)are
predicted to increase the risk of severe hypertension when
given withbeta 2 agonists. Avoid.rTheoretical
▶Safinamideis predicted to increase the risk of severe
hypertension when given withbeta 2 agonists.rTheoretical
▶Monoamine-oxidase B inhibitorsare predicted to increase the
risk of severe hypertension when given withbupropion. Avoid.
oTheoretical→Also seeTABLE 13p. 850
▶Combined hormonal contraceptivesslightly increase the
exposure torasagiline.oStudy
▶Combined hormonal contraceptivesincrease the exposure to
selegiline. Avoid.rStudy
▶Hormone replacement therapyis predicted to increase the
exposure toselegiline. Avoid.oStudy
▶Monoamine-oxidase B inhibitorsare predicted to increase the
effects oflevodopa. Adjust dose.nStudy→Also seeTABLE 8
p. 848
▶Monoamine-oxidase B inhibitors(rasagiline, selegiline)are
predicted to increase the risk of side-effects when given with
linezolid. Avoid and for 14 days after stopping the MAOI.
rTheoretical→Also seeTABLE 13p. 850
▶Safinamideis predicted to increase the risk of side-effects
when given withlinezolid. Avoid and for 1 week after stopping
safinamide.rTheoretical→Also seeTABLE 13p. 850
▶Monoamine-oxidase B inhibitors(rasagiline, selegiline)are
predicted to increase the risk of a hypertensive crisis when
given withmethylphenidate. Avoid.rTheoretical
▶Moclobemideis predicted to increase the effects ofmonoamine-
oxidase B inhibitors(rasagiline, selegiline). Avoid.r
Theoretical→Also seeTABLE 13p. 850
▶Moclobemideis predicted to increase the risk of side-effects
when given withsafinamide. Avoid and for 1 week after
stoppingsafinamide.rTheoretical→Also seeTABLE 13p. 850
▶Monoamine-oxidase B inhibitors(rasagiline, selegiline)are
predicted to increase the risk of side-effects when given with
monoamine-oxidase A and B inhibitors, irreversible. Avoid and
for 14 days after stopping the MAOI.rTheoretical→Also
seeTABLE 8p. 848→Also seeTABLE 13p. 850
▶Safinamideis predicted to increase the risk of side-effects
when given withmonoamine-oxidase A and B inhibitors,
irreversible. Avoid and for 1 week after stoppingsafinamide.
rTheoretical→Also seeTABLE 13p. 850
▶Rasagilineis predicted to increase the risk of side-effects when
given withopioids(pethidine). Avoid and for 14 days after
stoppingrasagiline.rTheoretical→Also seeTABLE 13p. 850
▶Safinamideis predicted to increase the risk of side-effects
when given withopioids(pethidine). Avoid and for 1 week after
stoppingsafinamide.rTheoretical→Also seeTABLE 13p. 850
▶Selegilineincreases the risk of side-effects when given with
opioids(pethidine). Avoid.rAnecdotal→Also seeTABLE 13
p. 850958 Monoamine-oxidase A and B inhibitors—Monoamine-oxidase B inhibitors BNFC 2018 – 2019
Interactions|Appendix 1A1